MedTrace Logo

A Study to Evaluate Change in Viral Load After OPN-019 in Adults With COVID-19

NCT05035576 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 8

Last updated 2022-05-02

No results posted yet for this study

Summary

The purpose of this study is to determine both the magnitude and duration of viral load (copies/mL) reduction after a single dose of OPN-019. The variability associated with viral counts will be utilized to inform the study design of future studies.

Conditions

  • Covid19

Interventions

DRUG

OPN-019

400 mg OPN-019, 2 sprays per nostril (one dose)

Sponsors & Collaborators

  • Optinose US Inc.

    lead INDUSTRY

Principal Investigators

  • Jennifer Carothers · OptiNose US

  • John Messina · OptiNose US

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-09-01
Primary Completion
2021-11-30
Completion
2021-11-30

Countries

  • Mexico

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05035576 on ClinicalTrials.gov